Nyxoah, a company developing disruptive neurostimulation technology to cure obstructive sleep apnea, mandated TCD Capital for supporting a capital increase. Established in Mont Saint Guibert, with R&D in Tel Aviv, Israel, the Company managed to close the capital increase, with a new Lead Investor, a Dutch Private Equity Fund and the existing club of shareholders.
That substantial capital increase allows the Company to have a new horizon up to the end of the CE marking phase, a substantial milestone in value creation.
At TCD Capital, we have supported more capital developments or invested into med and biotech, where Belgium based ventures consistently demonstrates a leadership. The strategy to market, the disruptive impact of the solution, the importance of the market place it addresses are all factors which may validate an investment option.